Surface-enhanced Raman scattering sensing platform for detecting amyloid-β peptide interaction with an aggregation inhibitor

Marcos A. Soares de Oliveira, Silvia Hilt, Che Wei Chang, Changwon Lee, John C Voss, James W. Chan

Research output: Contribution to journalArticlepeer-review

Abstract

Soluble, small amyloid-β oligomers (AβO) are recognized as significant contributors to the pathology of Alzheimer’s disease (AD). Although drugs for treating AD symptoms have been approved, no therapy targeting amyloid-β (Aβ) capable of modifying the course of the disease is available. In an effort to develop a label-free method for screening new anti-AD therapeutic agents, we show the use of a surface-enhanced Raman scattering (SERS) active substrate for detecting the interactions between Aβ peptides and spin-labeled fluorine (SLF), a peptide aggregation inhibitor. Changes in the peak positions and intensity ratios of two spectral peaks near 1600 cm1 and 2900 cm−1 can be used to monitor the molecular interactions between SLF and Aβ. This study demonstrates the potential of SERS spectroscopy for rapidly screening and identifying new anti-Aβ therapeutic agents.

Original languageEnglish (US)
Pages (from-to)7490-7495
Number of pages6
JournalApplied Optics
Volume59
Issue number25
DOIs
StatePublished - Sep 1 2020

ASJC Scopus subject areas

  • Atomic and Molecular Physics, and Optics
  • Engineering (miscellaneous)
  • Electrical and Electronic Engineering

Fingerprint

Dive into the research topics of 'Surface-enhanced Raman scattering sensing platform for detecting amyloid-β peptide interaction with an aggregation inhibitor'. Together they form a unique fingerprint.

Cite this